Focusing on value: how AI will change the face of consultancy
Eddie Gibson
Published 23 June 2026
LINK TO ARTICLE
How might the EU’s ‘innovation drain’ initiatives impact market access?
James Harris
Published 18 June 2026
LINK TO ARTICLE
Quality of quantity of life: Adopting EQ-5D-5L
Eddie Gibson
Published 15 June 2026
LINK TO ARTICLE
The natural history of osteogenesis imperfecta: a systematic review
Davide Gatti
Published 6 June 2026
LINK TO PUBLICATION
Market access is not working as well as it should – we need to understand how to make it better
Carsten Edwards
Published 15 May 2026
LINK TO ARTICLE
The evolution of pricing in pharma: when two worlds collide
Eddie Gibson
Published 13 May 2026
LINK TO ARTICLE
Can AI make pharmaceutical pricing smarter, faster and fairer?
Joshua Smith
Published 8 May 2026
LINK TO ARTICLE
Why early estimates beat late certainty – the art of extrapolation
Matthew Carter
Published 6 May 2026
LINK TO ARTICLE
Pricing under uncertain evidence: aligning value and pricing strategy early in rare diseases
Ellie Dorsman
Published 1 May 2026
LINK TO ARTICLE
Navigating a complex policy landscape: why market access must collaborate more closely across pharmaceutical functions
Eddie Gibson
Published 17 April 2026
LINK TO ARTICLE
Is regulatory myopia ruining your access evidence?
James Harris
Published 24 February 2026
LINK TO ARTICLE
Beyond reimbursement: optimising launch readiness through early integration of HTA and route-to-market planning
Alice Corbin
Published 17 February 2026
LINK TO ARTICLE
How might European sanctions interfere with the goal of lower drug prices in the US?
James Harris
Published 21 January 2026
LINK TO ARTICLE
Global expert consensus on the importance of secondary stroke prevention: challenges, care coordination and unmet needs for non-cardioembolic ischaemic stroke survivors
V Caso
Published 1 January 2026
LINK TO PUBLICATION
The clustered scoping review: A light-touch route to comprehensive, updatable evidence
Maria Rapoport
Published 1 November 2025
LINK TO ARTICLE
European pricing policy in 2025: balancing cost containment and innovation
Joshua Smith
Published 29 October 2025
LINK TO ARTICLE
Why is portfolio pricing so hard to get right?
Joshua Smith
Published 22 October 2025
LINK TO ARTICLE
Artificial intelligence (AI)-supported systematic review for rapid insights
Published 19 October 2025
DOWNLOAD PDF
Conceptualising alternative funding routes in women's health
Published 19 October 2025
DOWNLOAD PDF
Establishing real-world burden of a neurological condition in older adults
Published 19 October 2025
DOWNLOAD PDF
Clinical and economic impact of influenza and paediatric vaccination strategies
Published 19 October 2025
DOWNLOAD PDF
Microsimulation cost-effectiveness model for health technology assessment (HTA)
Published 19 October 2025
DOWNLOAD PDF
Survival analysis of patient-level data and economic modelling in immuno-oncology therapy
Published 19 October 2025
DOWNLOAD PDF
Testing payer reactions to a target product profile and trial concept
Published 19 October 2025
DOWNLOAD PDF
Reviewing health technology assessment (HTA) landscape in gastrointestinal (GI) cancer
Published 19 October 2025
DOWNLOAD PDF
Formulating stakeholder engagement strategy
Published 19 October 2025
DOWNLOAD PDF
Overcoming lack of robust data in rare and variable condition
Published 19 October 2025
DOWNLOAD PDF
Supporting a patient group in uplifting website user journey
Published 19 October 2025
DOWNLOAD PDF
Future-proofing organisational design whilst minimising disruption and dissatisfaction
Published 19 October 2025
DOWNLOAD PDF
Determining patient preference towards treatment characteristics
Published 19 October 2025
DOWNLOAD PDF
Modelling the cost effectiveness and capacity impact of supplemental screening for women with dense breasts
Published 19 October 2025
DOWNLOAD PDF
Pricing and launch sequencing strategy for a portfolio of infectious disease assets
Published 19 October 2025
DOWNLOAD PDF
Innovative approaches to estimating value-based pricing potential for early pipeline products
Published 19 October 2025
DOWNLOAD PDF
Evaluation of pricing strategy options across various markets in Europe and the Middle East
Published 19 October 2025
DOWNLOAD PDF
Expanding rare disease treatment access through a strategic health technology assessment (HTA) narrative
Published 19 October 2025
DOWNLOAD PDF
Translation of a value narrative into a global value dossier (GVD)
Published 19 October 2025
DOWNLOAD PDF
An innovative scoping review approach that combines artificial intelligence (AI) with effective reporting
Published 19 October 2025
DOWNLOAD PDF
Supporting health technology assessment (HTA) submissions with gold-standard review practice
Published 19 October 2025
DOWNLOAD PDF
Health policy under duress: tariff-pressured NICE threshold rises fail to address budget pressures and access inequities
Anne Loos
Published 17 October 2025
LINK TO ARTICLE
Could Trump’s MFN executive order require changes to early access program strategy?
Joshua Smith
Published 8 October 2025
LINK TO ARTICLE
A tale of two frameworks: What GRACE and evLYG reveal about the next era of value assessment
Anne Loos, Matthew Carter
Published 7 October 2025
LINK TO ARTICLE
The IMPACT Survey: The Humanistic Impact of Caring for an Individual with Osteogenesis Imperfecta
Ingunn Westerheim
Published 26 September 2025
LINK TO PUBLICATION
The IMPACT Survey: The Economic Impact of Caring for an Individual with Osteogenesis Imperfecta
Frank Rauch
Published 23 September 2025
LINK TO PUBLICATION
Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD
Ben Kluge
Published 10 September 2025
LINK TO PUBLICATION
Cost savings from prioritization of non-invasive modalities within CAD diagnostic protocols: a systematic review
Ben Kluge
Published 1 September 2025
LINK TO PUBLICATION
Trump administration demands delivery of ‘Most Favored Nation’ pricing
Joshua Smith
Published 1 August 2025
LINK TO ARTICLE
Germany drops international reference pricing. What does it mean for global pricing strategy?
Joshua Smith
Published 28 July 2025
LINK TO ARTICLE
FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
G Candore
Published 10 June 2025
LINK TO PUBLICATION
LLM-powered chatbots as a health information channel: how can stakeholder and communication strategy mitigate risks to informed decision making?
James Harris
Published 9 June 2025
LINK TO ARTICLE
MFN prescription drug pricing in the US: why the 2025 initiative differs from 2020
James Harris
Published 13 May 2025
LINK TO ARTICLE
Unlocking EU access: why joint scientific consultation matters for US biotechs
Anne Loos
Published 1 May 2025
LINK TO ARTICLE
Evidence first: How Joint Clinical Assessment is shaping US biotech market entry planning
Anne Loos
Published 24 April 2025
LINK TO ARTICLE
The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients
T Konta
Published 16 December 2024
LINK TO PUBLICATION
The IMPACT Survey: the humanistic impact of osteogenesis imperfecta in adults
Taco van Welzenis
Published 28 November 2024
LINK TO PUBLICATION
The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes
K Ashai
Published 22 November 2024
LINK TO PUBLICATION
Weighing the value of an ounce of prevention
Eddie Gibson
Published 14 November 2024
LINK TO ARTICLE
What are the implications of the JCA for the use of real-world evidence in Europe?
Annabel Suter
Published 11 November 2024
LINK TO ARTICLE
The NICE willingness-to-pay threshold: an appropriate valuation of health in 2024?
Molly Paffett
Published 7 November 2024
LINK TO ARTICLE
Capability, capacity, culture, and communication: Are you ready for the joint challenges of US and EU pharmaceutical market evolution?
Owen Daykin-Pont & Wittkiefer
Published 5 September 2024
LINK TO ARTICLE
Unmet need in pulmonary hypertension-associated interstitial lung disease (PH-ILD): a clinician survey of real-world management of PH-ILD in Europe
D Montani
Published 8 July 2024
LINK TO PUBLICATION
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
E Kastrtis
Published 1 July 2024
LINK TO PUBLICATION
Changes in market access in Spain: a gateway to enhanced efficiency?
Inés Pérez Román
Published 4 June 2024
LINK TO ARTICLE
The IMPACT Survey: the economic impact of osteogenesis imperfecta in adults
T Hart
Published 3 June 2024
LINK TO PUBLICATION
Derivation of utilities from discrete choice experiments
Owen Daykin-Pont
Published 24 April 2024
LINK TO ARTICLE
The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers
I Westerheim
Published 21 March 2024
LINK TO PUBLICATION
How can a company’s organisational design bring market access closer to clinical development?
Maya Patt
Published 7 November 2023
LINK TO ARTICLE
Multimorbidity: opportunities for pharma to add value
Amy Cooper
Published 3 November 2023
LINK TO ARTICLE
Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey
A Fuat
Published 29 October 2023
LINK TO PUBLICATION
Employers and the pharmaceutical industry - natural partners in optimising working-age access to healthcare?
Rachel Thomas
Published 26 October 2023
LINK TO ARTICLE
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)
A Jansen
Published 11 October 2023
LINK TO PUBLICATION
The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease.
F Groehl
Published 1 October 2023
LINK TO PUBLICATION
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
V Peirce
Published 26 September 2023
LINK TO PUBLICATION
Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort.
A Lucchesi
Published 7 September 2023
LINK TO PUBLICATION
Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases.
E Gibson
Published 10 August 2023
LINK TO PUBLICATION
Intrapatient controlled trials: barrier or opportunity for gene therapy reimbursement?
Ellie Dorseman
Published 10 August 2023
LINK TO ARTICLE
Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.
P Rossing
Published 26 July 2023
LINK TO PUBLICATION
Performance of Supplemental Imaging Modalities for Breast Cancer in Women With Dense Breasts: Findings From an Umbrella Review and Primary Studies Analysis.
F Lobig
Published 5 July 2023
LINK TO PUBLICATION
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermediate breast cancer risk in US healthcare
M Blankenburg
Published 30 June 2023
LINK TO PUBLICATION
The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review
M Rapoport
Published 22 February 2023
LINK TO PUBLICATION
Evaluation of health economic impact of initial diagnostic modality selection for colorectal cancer liver metastases in suspected patients in China, Japan and the USA
M Blankenburg
Published 10 February 2023
LINK TO PUBLICATION
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
V Caso
Published 11 January 2023
LINK TO PUBLICATION
Understanding the risk of developing weight-related complications associated with different body mass index categories: a systematic review.
AB Taieb
Published 7 December 2022
LINK TO PUBLICATION
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis
C Blomstrom
Published 7 September 2022
LINK TO PUBLICATION
Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA
M Blankenburg
Published 19 August 2022
LINK TO PUBLICATION
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
L Fan
Published 8 June 2022
LINK TO PUBLICATION
Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome.
A Strzelczyk
Published 6 June 2022
LINK TO PUBLICATION
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)
V McDonald
Published 2 October 2021
LINK TO PUBLICATION
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.
S Johal
Published 28 June 2021
LINK TO PUBLICATION
Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma
E Gibson
Published 6 May 2020
LINK TO PUBLICATION
Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature
S Schubert-Bast
Published 1 September 2019
LINK TO PUBLICATION
A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany
A Strzelczyk
Published 20 June 2019
LINK TO PUBLICATION
Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: A prospective, multicenter study from Germany.
A Strzelczyk
Published 1 May 2019
LINK TO PUBLICATION
Caregiver impact and health service use in high and low severity Dravet syndrome: A multinational cohort study
L Lagae
Published 1 February 2019
LINK TO PUBLICATION
Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma
E Gibson
Published 30 January 2019
LINK TO PUBLICATION
The Problem of Rarity: Estimation of Prevalence in Rare Disease.
S Auvin
Published 5 April 2018
LINK TO PUBLICATION
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.
E Gibson
Published 8 March 2018
LINK TO PUBLICATION
Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey
L Lagae
Published 6 October 2017
LINK TO PUBLICATION
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
E Gibson
Published 2 September 2017
LINK TO PUBLICATION
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.
Z Kalo
Published 5 July 2017
LINK TO PUBLICATION
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles
E Gibson
Published 28 June 2016
LINK TO PUBLICATION
Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review
E Gibson
Published 8 April 2016
LINK TO PUBLICATION
Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections
S Karve
Published 1 March 2016
LINK TO PUBLICATION
